The safety and efficacy of intracoronary nitrite infusion during acute myocardial infarction (NITRITE-AMI): study protocol of a randomised controlled trial

D A Jones, M Andiapen, T J A Van-Eijl, A J Webb, S Antoniou, R J Schilling, A Ahluwalia, A Mathur, D A Jones, M Andiapen, T J A Van-Eijl, A J Webb, S Antoniou, R J Schilling, A Ahluwalia, A Mathur

Abstract

Introduction: Acute myocardial infarction (AMI) is a major cause of death and disability in the UK and worldwide. Presently, timely and effective reperfusion with primary percutaneous coronary intervention (PPCI) remains the most effective treatment strategy for limiting infarct size, preserving left ventricular ejection fraction (LVEF) and improving clinical outcomes. However, the process of reperfusion can itself induce cardiomyocyte death, known as myocardial reperfusion injury, for which there is currently no effective therapy. Extensive preclinical evidence exists to suggest that sodium nitrite (as a source of endogenous nitric oxide) is an effective therapeutic strategy for preventing myocardial reperfusion injury. The purpose of NITRITE-AMI is to test whether sodium nitrite reduces reperfusion injury and subsequent infarct size in patients undergoing PPCI for MI.

Methods and design: NITRITE-AMI is a double-blind, randomised, single-centre, placebo-controlled trial to determine whether intracoronary nitrite injection reduces infarct size in patients with myocardial infarction undergoing primary angioplasty. The study will enrol 80 patients presenting with ST-elevation myocardial infarction. Patients will be randomised to receive either a bolus of intracoronary sodium nitrite or placebo (sodium chloride) at the time of PPCI. The primary outcome is infarct size assessed by creatine kinase area under the curve (AUC) over 48 h. Secondary endpoints include troponin T AUC and infarct size, LV dimensions and myocardial salvage index assessed by cardiac MR (CMR), markers of platelet reactivity and inflammation, the safety and tolerability of intracoronary nitrite, and 1 year major adverse cardiac events.

Ethics and dissemination: The study is approved by the local ethics committee (NRES Committee London West London: 11/LO/1500) and by the Medicines and Healthcare Products Regulatory Agency (MHRA) (EudraCT nr. 2010-022460-12). The results of the trial will be published according to the CONSORT statement and will be presented at conferences and reported in peer-reviewed journals.

Trial registration: United Kingdom Clinical Research Network (Study ID 12117), https://ichgcp.net/clinical-trials-registry/NCT01584453" title="See in ClinicalTrials.gov">NCT01584453) and Current Controlled Trials (ISRCTN:38736987).

Figures

Figure 1
Figure 1
Flow diagram of study design.

References

    1. Lambert L, Brown K, Segal E, et al. Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction. JAMA 2010;303:2148–55
    1. Berger PB, Ellis SG, Holmes DR, Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction. Results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial. Circulation 1999;100:14–20
    1. McNamara RL, Wang Y, Herrin J, et al. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2006;47:2180–6
    1. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941–7
    1. Smith EJ, Mathur A. Rothman MT recent advances in primary percutaneous intervention for acute myocardial infarction. Heart 2005;91:1533–6
    1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13–20
    1. Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 2010;31:943–57
    1. McAlister FA, Quan H, Fong A, et al. Effect of invasive coronary revascularization in acute myocardial infarction on subsequent death rate and frequency of chronic heart failure. Am J Cardiol 2008;102:1–5
    1. Burns RJ, Gibbons RJ, Yi Q, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002;39:30–6
    1. Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 2008;94:730–6
    1. Gibbons RJ, Valeti US, Araoz PA, et al. The quantification of infarct size. J Am Coll Cardiol 2004;44:1533–42
    1. Majidi M, Kosinski AS, Al-Khatib SM, et al. Reperfusion ventricular arrhythmia ‘bursts’ predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction. Eur Heart J 2009;30:757–64
    1. Timmer JR, Breet N, Svilaas T, et al. Predictors of ventricular tachyarrhythmia in high-risk myocardial infarction patients treated with primary coronary intervention. Neth Heart J 2010;18:122–8
    1. Saia F, Grigioni F, Marzocchi A, et al. Management of acute left ventricular dysfunction after primary percutaneous coronary intervention for ST elevation acute myocardial infarction. Am Heart J 2010;160:S16–21
    1. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000;190:255–66
    1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Eng J Med 2007;357:1121–35
    1. Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J 2009;30:2193–203
    1. Eshaghian S, Shah PK, Kaul S. Advances in antiplatelet treatment for acute coronary syndromes. Heart 2010;96:656–61
    1. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218–30
    1. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473–81
    1. Bryan NS, Fernandez BO, Bauer SM, et al. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol 2005;1:290–7
    1. Webb AJ, Patel N, Loukogeorgakis S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 2008;51:784–90
    1. Li H, Cui H, Kundu TK, et al. Nitric oxide production from nitrite occurs primarily in tissues not in the blood. J Biol Chem 2008;283:17855–63
    1. Feelisch M, Fernandez BO, Bryan NS, et al. Tissue processing of nitrite in hypoxia an intricate interplay of nitric oxide-generating and-scavenging systems. J Biol Chem 2008;283:33927–34
    1. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008;7:156–67
    1. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 2007;42:271–9
    1. Bredt DS. Nitric oxide signaling specificity—the heart of the problem. J Cell Sci 2003;116:9–15
    1. Giraldez RR, Panda A, Xia Y, et al. Decreased nitric-oxide synthase activity causes impaired endothelium-dependent relaxation in the postischemic heart. J Biol Chem 1997;272:21420–6
    1. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001;33:1897–918
    1. Moens AL, Claeys MJ, Timmermans JP, et al. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 2005;100:179–90
    1. Johnson G, III, Tsao PS, Lefer AM. Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit Care Med 1991;19:244–52
    1. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci 1991;88:4651.
    1. Ahluwalia A, Foster P, Scotland RS, et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 2004;101:1386–91
    1. Palazzo AJ, Jones SP, Girod WG, et al. Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient mice. Am J Physiol 1998;275:H2300–7
    1. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 2006;40:16–23
    1. Razavi HM, Hamilton JA, Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther 2005;106:147–62
    1. Dorn GW. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Natl Rev Cardiol 2009;6:283–91
    1. Webb A, et al. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia/reperfusion damage. Proc Natl Acad Sci USA 2004;101:13683–88
    1. Duranski MR, Greer JJ, Dejam A, et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest 2005;115:1232–40
    1. Pluta RM, Dejam A, Grimes G, et al. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA 2005;293:1477–84
    1. Jung KH, Chu K, Ko SY, et al. Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury. Stroke 2006;37:2744–50
    1. Tripatara P, Patel NSA, Webb A, et al. Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol 2007;18:570–80
    1. Baker JE, Su J, Fu X, et al. Nitrite confers protection against myocardial infarction: role of xanthine oxidoreductase, NADPH oxidase and K(ATP) channels. J Mol Cell Cardiol 2007;43:437–44
    1. Hendgen-Cotta UB, Merx MW, Shiva S, et al. Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. Proc Natl Acad Sci USA 2008;105:10256.
    1. Gonzalez FM, Shiva S, Vincent PS, et al. Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation 2008;117:2986–94
    1. Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003;9:1498–505
    1. Dejam A, Hunter CJ, Tremonti C, et al. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation 2007;116:1821–31
    1. Maher AR, Milsom AB, Gunaruwan P, et al. Hypoxic modulation of exogenous nitrite-induced vasodilation in humans. Circulation 2008;117:670–7
    1. Chia S, Senatore F, Raffel OC, et al. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008;1:415–23
    1. Grande P, Christiansen C, Alstrup K. Comparison of ASAT, CK, CK-MB, and LD for the estimation of acute myocardial infarct size in man. Clin Chim Acta 1983;128:329–35
    1. Turer AT, Mahaffey KW, Gallup D, et al. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med 2005;6:12.
    1. Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging 2011;4:150–6
    1. Alderman EL, Stadius M. The angiographie definitions of the bypass angioplasty revascularization investigation. Coron Artery Dis 1992;3:1189–208
    1. Ortiz-Perez JT, Meyers SN, Lee DC, et al. Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. Eur Heart J 2007;28:1750–8
    1. Wright J, Adriaenssens T, Dymarkowski S, et al. Quantification of myocardial area at risk with T2-weighted CMR: comparison with contrast-enhanced CMR and coronary angiography. JACC: Cardiovasc Imaging 2009;2:825–31
    1. Staat P, Rioufol G, Piot C, et al. Postconditioning the Human Heart. Circulation 2005;112:2143–8

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する